Should Investors Buy the Dip With Bluebird Bio Stock?

With the stock down 52% in the last three months, Bluebird Bio (NASDAQ: BLUE) shareholders are bound to be feeling pretty antsy. Between the company's weak cash position, missed deadline for a drug candidate submission to regulators, and 30% cut in its workforce a year ago, there hasn't been much to celebrate lately. First, while it did miss its goal of submitting its approval packet for a therapy called lovo-cel to the Food and Drug Administration (FDA) in the first quarter, it says that once the FDA gets back to it in a few weeks, it'll do so.